

Supplementary table 1

The relationship of CASC2 expression with pathological parameters

Clinicopathological parameters			CASC2	
		n	Relative expression	P
Age, y	< 60	22	0.5454±0.1441	0.7865
	≥60	16	0.4859±0.1614	
Stage	I	34	0.5807±0.1144	0.0982
	II+III+IV	4	0.007284±0.004149	
Differentiation	High+ Middle	31	0.6200±0.1234	0.0469*
	Low	7	0.07902±0.02817	
Invasion depth	<1/2	27	0.5747±0.1226	0.4303
	>1/2	11	0.3869±0.2143	
Lymphatic metastasis	No	36	0.5485±0.1103	0.2666
	Yes	2	0.01351±0.005075	

Supplementary table 2

Sequences of plasmid and RNA oligo/inhibitor

Name	Sequence
LV-CASC2-RNAi (67669-1)	GCAGATGGAGATTCAGAAACA
LV-CASC2-RNAi (67670-1)	AGTAAGAAGTGTGTTGCATGA
LV-CASC2-RNAi (67671-1)	CTGCTACTTGCCTTTGTAAAT
LV-NC	TTCTCCGAACGTGTCACGT
NC	Sense: 5'-UUCUCCGAACGUGUCACGUTT-3'
	Antisense: 5'-ACGUGACACGUUCGGAGAATT-3'
hsa-miR-103a-3p mimics	Sense: 5'-AGCAGCAUUGUACAGGGCUAUGA-3'
	Antisense: 5'-AUAGCCCUGUACAAUGCUGCUUU-3'
hsa-miR-107 mimics	Sense: 5'-AGCAGCAUUGUACAGGGCUAUGA-3'
	Antisense: 5'-AUAGCCCUGUACAAUGCUGCUUU-3'
inhibitor NC	5'-UUGUACUACACAAAAGUACUG-3'
hsa-miR-103a-3p inhibitor	5'-UCAUAGCCCUGUACAAUGCUGCU-3'
hsa-miR-107 inhibitor	5'-UGAUAGCCCUGUACAAUGCUGCU-3'
Si-PLAG1	sense: 5'-AUUAUACUCUUCUAAAAACCTT-3
	antisense: 5'-GGUUUUUAGAAGAGUAUAUAUTT-3'

Supplementary table 3

Primer sequence.

Gene Name	Primer Sequence
CASC2	F: GAGACACAGCTGGGCTGAAC R: TCACATCACCATGGGCAAGC
hsa-miR-103a-3p	F: GAGCAGCATTGTACAGGGCTATGA
hsa-miR-107	F: CAGCAGCATTGTACAGGGCTATCA
PLAG1	F: GCCGCAACAAGTGGTGACCTC R: CCAGACGACTTGCCTGCATGAG
IGF2	F: CTGGAGACGTACTGTGCTAC R: CATATTGGAAGAACTTGCCAC
GAPDH	F: GCACCGTCAAGGCTGAGAAC R: TGGTGAAGACGCCAGTGGA
U6	F: CGGGTTTGTTTGCATTTCT R: AGTCCCAGCATGAACAGCTT

F: Forward; R: Reverse.

Supplementary table 4

Primary antibodies used for the detection of protein expression

Name	Manufacturer	Dilution ratio: Western blotting,
PLAG1	Proteintech, Hangzhou, China	1:1000
IGF2	Zen Bioscience, Chengdu, China	1:500
MMP-2	Wanleibio, Shenyang, China	1:500
MMP-9	Proteintech, Hangzhou, China	1:500
BAD	Proteintech, Hangzhou, China	1:1000
BCL-2	Proteintech, Hangzhou, China	1:2000
BCL-XL	Proteintech, Hangzhou, China	1:2000
BAX	Proteintech, Hangzhou, China	1:4000
GAPDH	Proteintech, Hangzhou, China	1:10000

Supplementary materials

Figure S1: The relationship between CASC2 expression and grade or stage in the TCGA database.





Figure S2: Fluorescent Photo of CASC2 Virus Transfection Efficiency

Ishikawa



HEC-1A




Figure S3: Expression and survival prognosis of mir-103-3p, mir-107, PLAG1, IGF2 in TCGA database in endometrial cancer. Expression of IGF2 protein in CPTAC database in endometrial cancer











Figure S4: Verification of transfection efficiency of mir-103a-3p / mir-107 mimics and mir-103a-3p / mir-107 inhibitors by RT-PCR

